ATE239035T1 - Durch hla-b44 moleküle präsentierte tumor- abstossungsantigene und ihre verwendungen - Google Patents

Durch hla-b44 moleküle präsentierte tumor- abstossungsantigene und ihre verwendungen

Info

Publication number
ATE239035T1
ATE239035T1 AT97906894T AT97906894T ATE239035T1 AT E239035 T1 ATE239035 T1 AT E239035T1 AT 97906894 T AT97906894 T AT 97906894T AT 97906894 T AT97906894 T AT 97906894T AT E239035 T1 ATE239035 T1 AT E239035T1
Authority
AT
Austria
Prior art keywords
tumor rejection
hla
molecules
rejection antigens
antigens presented
Prior art date
Application number
AT97906894T
Other languages
English (en)
Inventor
Jean Herman
Pierre Coulie
Thierry Boon-Falleur
Der Bruggen Pierre Van
Immanuel Luescher
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of ATE239035T1 publication Critical patent/ATE239035T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT97906894T 1996-02-20 1997-02-05 Durch hla-b44 moleküle präsentierte tumor- abstossungsantigene und ihre verwendungen ATE239035T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/602,506 US6060257A (en) 1994-06-03 1996-02-20 Tumor rejection antigens presented by HLA-B44 molecules, and uses thereof
PCT/US1997/001915 WO1997031017A1 (en) 1996-02-20 1997-02-05 Tumor rejection antigens presented by hla-b44 molecules, and uses thereof

Publications (1)

Publication Number Publication Date
ATE239035T1 true ATE239035T1 (de) 2003-05-15

Family

ID=24411635

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97906894T ATE239035T1 (de) 1996-02-20 1997-02-05 Durch hla-b44 moleküle präsentierte tumor- abstossungsantigene und ihre verwendungen

Country Status (12)

Country Link
US (2) US6060257A (de)
EP (1) EP0876397B1 (de)
JP (1) JP3256749B2 (de)
KR (1) KR19990087064A (de)
CN (1) CN1214692A (de)
AT (1) ATE239035T1 (de)
AU (1) AU711912B2 (de)
CA (1) CA2246222C (de)
DE (1) DE69721485T2 (de)
NZ (1) NZ331398A (de)
WO (1) WO1997031017A1 (de)
ZA (1) ZA971403B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977300A (en) * 1994-06-03 1999-11-02 Ludwig Institute Of Cancer Research Isolated nonapeptide which bind to HLA-B44 molecules and the uses thereof
CN1082444C (zh) 1994-12-29 2002-04-10 佳能株式会社 采用具有多个喷墨加热器的喷墨头的喷墨设备
US6503703B1 (en) 1995-05-19 2003-01-07 Mount Sinai School Of Medicine Of New York University Identification and use of antiviral compounds that inhibit interaction of host cell proteins and viral proteins required for viral replication
CA2274737A1 (en) * 1996-12-12 1998-06-18 Visible Genetics, Inc. Method and kit for hla class i typing
HK1046925A1 (zh) * 1999-10-19 2003-01-30 Ludwig Institute For Cancer Research Mage-a12抗原肽及其用途
US6897288B1 (en) 1999-10-19 2005-05-24 Ludwig Institute For Cancer Research Mage-A12 antigenic peptides and uses thereof
ATE395930T1 (de) 1999-10-22 2008-06-15 Aventis Pasteur Verfahren zur erregung und/oder verstärkung der immunantwort gegen tumorantigene
EP1266221A1 (de) * 2000-01-20 2002-12-18 Ludwig Institute For Cancer Research An hla-b35 und hla-b44 bindende mage antigene peptide
AU2001253029A1 (en) * 2000-03-30 2001-10-15 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services T-cell epitope of mage-12 and related nucleic acids, vectors, cells, compositions and methods of inducing an immune response to cancer
DK1282702T3 (da) 2000-05-10 2007-04-02 Sanofi Pasteur Ltd Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf
WO2004027036A2 (en) * 2002-09-19 2004-04-01 Johns Hopkins University School Of Medicine Cancer immunotherapy with a viral antigen-defined, immunomodulator-secreting cell vaccine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235525B1 (en) * 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US5541104A (en) * 1991-05-23 1996-07-30 Ludwig Institute For Cancer Research Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1
ES2225824T3 (es) * 1992-08-31 2005-03-16 Ludwig Institute For Cancer Research Nonapeptido aislado derivado del gen mage-3 y presentado por hla-a1, y sus usos.
US5405940A (en) * 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof
US5558995A (en) * 1993-01-22 1996-09-24 Ludwig Institute For Cancer Research Peptides which are derived from tumor rejection antigen precursor molecule MAGE-1, which complex to MHC molecule HLA-C clone 10, and uses thereof
US5977300A (en) * 1994-06-03 1999-11-02 Ludwig Institute Of Cancer Research Isolated nonapeptide which bind to HLA-B44 molecules and the uses thereof

Also Published As

Publication number Publication date
AU711912B2 (en) 1999-10-21
CA2246222A1 (en) 1997-08-28
NZ331398A (en) 1999-03-29
KR19990087064A (ko) 1999-12-15
DE69721485D1 (de) 2003-06-05
EP0876397A1 (de) 1998-11-11
EP0876397B1 (de) 2003-05-02
JP3256749B2 (ja) 2002-02-12
CN1214692A (zh) 1999-04-21
US5744353A (en) 1998-04-28
WO1997031017A1 (en) 1997-08-28
JPH11512622A (ja) 1999-11-02
EP0876397A4 (de) 1999-08-18
AU2261497A (en) 1997-09-10
ZA971403B (en) 1997-10-10
CA2246222C (en) 2002-01-08
US6060257A (en) 2000-05-09
DE69721485T2 (de) 2003-11-27

Similar Documents

Publication Publication Date Title
FI963779A7 (fi) MAGE-kasvainhyljintäantigeeniprekursoreista saatuja eristettyjä peptid ejä, jotka kompleksoituvat HLA-A2-molekyylien kanssa
FI963780A7 (fi) Kasvainhyljintäantigeeniprekursorista MAGE-2 saatuja eristettyjä pepti dejä ja niiden käyttöjä
EP1090924A4 (de) Von cyclophilin b abstammende tumorantigen-peptide
TR200301846T2 (tr) Cripto bloke edici Antikorlar ve bu antikorların kullanımları.
BR9707819A (pt) Imunogenos peptidicos
ATE255906T1 (de) Antikörper gegen cd40
WO2000078344A8 (en) Prion protein peptides and uses thereof
ZA952374B (en) Isolated peptides derived from MAGE antigen precursors which complex with HLA-A2 molecules and uses thereof
ZA986277B (en) Tumor rejection antigens presented by HLA-B44 molecules and uses thereof
ATE239035T1 (de) Durch hla-b44 moleküle präsentierte tumor- abstossungsantigene und ihre verwendungen
DE69714451D1 (de) Prionbindende proteine und deren verwendungen
CA2184175A1 (en) Isolated, tyrosinase derived peptides and uses thereof
ATE316574T1 (de) Verwendung von ulip proteinen zur diagnose und therapie von krebs und paraneoplastischen neurologischen syndromen
UY26266A1 (es) Antigeno asociado con tumores (r11) ley 17164
WO2001029220A3 (en) Mage-a12 antigenic peptides and uses thereof
ATE209041T1 (de) Durch hla-b44 moleküle präsentierte tumor- abstossungsantigene und ihre verwendung
DE69942637D1 (de) Zusammensetzungen und verfahren für die therapie und diagnose von ovariumkrebs
FI963170A0 (fi) Menetelmä solujen poikkeavuudesta kärsivien yksilöiden tunnistamiseks i
AU653332B2 (en) Synthetic peptides which contain sequences from factor VIIa, and the use thereof
ZA958037B (en) Tumor rejection antigens presented by HLA-b44 molecules and uses thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0876397

Country of ref document: EP

REN Ceased due to non-payment of the annual fee